Fig. 3: Tolododekin-alfa treatment results in remodeling of the tumor microenvironment as observed by gene expression changes. | Nature Communications

Fig. 3: Tolododekin-alfa treatment results in remodeling of the tumor microenvironment as observed by gene expression changes.

From: Interleukin-12 anchored drug conjugate (tolododekin alfa) in patients with advanced solid tumors: first-in-human Phase 1 trial

Fig. 3

A–D Transcriptional analysis (Nanostring IO360TM Panel) of tumor tissue biopsies collected at baseline (C1D1) and 21 days post-treatment after one dose of tolododekin alfa (C2D1), n = 8 patients. A The “All Signatures” forest plot shows the differential expression between time points (C2D1 vs C1D1) for each signature on an unadjusted scale. The vertical axis is shown at fold change equal to zero; the “black triangle” indicates a significant difference in the signature as assessed by univariate analysis (significance is not adjusted for multiple comparisons). B Volcano plot shows the most highly upregulated IL-12 pathway-related genes as indicated, two-sided statistical analysis was performed. C The heatmap displays differential signature score per patient across all evaluable dosing cohorts, in all tumor types assessed, and in both injected and non-injected tumors, after one cycle (C2D1) and after three cycles of doing (C4D1). D Upregulation of the Tumor Inflammatory Score (TIS) and CD8+ T cell gene signatures were associated with treatment outcomes, a total of 8 patients (n = 6 (SD) and n = 2 (PD). Mean ± SEM is indicated in the bar graphs. Two-sided P values were calculated per paired t-test. *indicates p = 0.05, **indicates p = 0.009.

Back to article page